The GBMRP recognizes the critical need for improved outcomes for individuals with glioblastoma.
The GBMRP FY24 Transformative Consortium Award (TCA) is designed to support a multidisciplinary collaborative effort of at least four, but not more than five, distinct yet complementary projects that
collectively address a central hypothesis.
Applications for the TCA may propose clinical or translational research projects and/or clinical trials and must address at least one of the FY24 GBMRP Areas of Emphasis.
This award requires a team-based approach by a consortium of exceptional researchers and at least one consumer advocate, whose collaborative efforts will catalyze scientific discovery, drive innovation, and make breakthroughs that could not be accomplished by a single investigator or group.